European Archives - Page 151 of 1507 - European Medical Journal

Debate grows over ERAP2 as ovarian ageing biomarker

Debate Grows Over ERAP2 as Ovarian Ageing Biomarker

Researchers are debating whether ERAP2 can serve as a reliable ageing-derived biomarker for premature ovarian insufficiency, reflecting underlying biological ageing.

Regenerative Hepatology

Learn more about regenerative hepatology in this series featuring Ludovic Vallier, an expert on the development of clinically relevant cell types from human pluripotent stem cells

Pallidal Beta Power Linked to Depression in Parkinson’s

Pallidal Beta Power Linked to Depression in Parkinson’s

Elevated pallidal beta power may serve as a biomarker for depression in Parkinson’s disease, paving the way for targeted DBS therapies. Learn more.

Acne Risk Rises Markedly After Gender-Affirming Hormone Therapy

Acne Risk Rises Markedly After Gender-Affirming Hormone Therapy

Acne risk rises sharply in transmasculine individuals starting testosterone and also affects transfeminine patients on estradiol. Read more.

deep brain stimulation

What Are the Risks of Deep Brain Stimulation?

Discover why deep brain stimulation may be safer than expected and how large scale data could change surgical decision making.

Machine Learning Aids Prognosis in Upper Tract Urothelial Cancer

Machine learning models accurately predict survival after surgery for upper tract urothelial cancer, supporting personalised follow up and adjuvant treatment decisions.

Hidden Mpox Exposure Found Among Healthy Adults

New sero-genomic research suggests hidden mpox exposure in healthy Nigerian adults, highlighting residual smallpox immunity and surveillance gaps.

CAR-T Cell Therapy Induces Durable Remission in SLE

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Optimising Continuous Infusion Therapy in Advanced Parkinson’s Disease

This infographic offers consensus-based guidance on the real-world use of LDp/CDp for patients with advanced…

Hetrombopag Effective in Paediatric Immune Thrombocytopenia

Hetrombopag achieved an overall response in over three quarters of paediatric patients with immune thrombocytopenia, with durable responses and no serious adverse events reported.